Oxford BioDynamics launches EpiSwitch oncology test

By LabPulse.com staff writers

February 28, 2022 -- Oxford BioDynamics announced the clinical validation and U.S. launch of its EpiSwitch checkpoint inhibitor response test (CiRT) for oncology.

The blood test predicts the likelihood of a cancer patient's response to immune checkpoint inhibitors (ICIs), including anti-programmed cell death ligand 1 (anti-PD-L1) and anti-PD-1 immunotherapies. The test aims to enable doctors to make informed decisions on whether to recommend beginning or continuing treatment with an ICI. Also, it aims to allow clinicians to make a treatment decision without the need of a biopsy.

Personal Genome Diagnostics touts liquid biopsy data
Personal Genome Diagnostics reported positive study results for a 58-gene panel liquid biopsy test for assessing microsatellite instability and tumor...
Blood work tracks immunotherapy in GI cancers
Researchers in China have identified proteins in the blood that may help show which patients with cancer of the gastrointestinal (GI) tract are responding...

Copyright © 2022 LabPulse.com

Last Updated ls 2/28/2022 4:14:55 PM